Harbeck N, et al. - Researchers performed a combined analysis of two pivotal registration studies to support evidence on safety for biosimilar filgrastim EP2006 in patients with breast cancer receiving myelosuppressive chemotherapy, a sensitive clinical setting to confirm biosimilarity of filgrastim. In patients with breast cancer, biosimilar filgrastim demonstrated a safety profile consistent with previous filgrastim studies and was efficient in preventing febrile neutropenia.